NO323295B1 - Anvendelse av H+,K+-ATPase-inhibitorer for fremstilling av oralt administrerbare medikamenter for inhibering av magesyresekresjon - Google Patents
Anvendelse av H+,K+-ATPase-inhibitorer for fremstilling av oralt administrerbare medikamenter for inhibering av magesyresekresjon Download PDFInfo
- Publication number
- NO323295B1 NO323295B1 NO19985964A NO985964A NO323295B1 NO 323295 B1 NO323295 B1 NO 323295B1 NO 19985964 A NO19985964 A NO 19985964A NO 985964 A NO985964 A NO 985964A NO 323295 B1 NO323295 B1 NO 323295B1
- Authority
- NO
- Norway
- Prior art keywords
- inhibitor
- alkoxy
- atpase
- hydrogen
- omeprazole
- Prior art date
Links
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 title claims abstract description 9
- 230000005764 inhibitory process Effects 0.000 title claims description 20
- 239000003814 drug Substances 0.000 title claims description 12
- 229940079593 drug Drugs 0.000 title claims description 5
- 230000009858 acid secretion Effects 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 5
- 210000002784 stomach Anatomy 0.000 title description 3
- 238000002483 medication Methods 0.000 title 1
- 230000036470 plasma concentration Effects 0.000 claims abstract description 9
- 229940121819 ATPase inhibitor Drugs 0.000 claims abstract description 7
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 18
- 229960000381 omeprazole Drugs 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 230000027119 gastric acid secretion Effects 0.000 claims description 11
- 210000002381 plasma Anatomy 0.000 claims description 11
- 150000002431 hydrogen Chemical group 0.000 claims description 10
- 230000002035 prolonged effect Effects 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 159000000011 group IA salts Chemical class 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- -1 piperidino, morpholino Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002071 phenylalkoxy group Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 238000013265 extended release Methods 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000612 proton pump inhibitor Substances 0.000 description 20
- 229940126409 proton pump inhibitor Drugs 0.000 description 19
- 239000002253 acid Substances 0.000 description 11
- 210000004211 gastric acid Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 201000000052 gastrinoma Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102000003697 P-type ATPases Human genes 0.000 description 1
- 108090000069 P-type ATPases Proteins 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010013864 duodenitis Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229950007395 leminoprazole Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- KWORUUGOSLYAGD-UHFFFAOYSA-N magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C.N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-UHFFFAOYSA-N 0.000 description 1
- MQEUGMWHWPYFDD-UHFFFAOYSA-N magnesium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical class [Mg].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C MQEUGMWHWPYFDD-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940089505 prilosec Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 230000017619 regulation of gastric acid secretion Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9602442A SE9602442D0 (sv) | 1996-06-20 | 1996-06-20 | Administration of pharmaceuticals |
| PCT/SE1997/001098 WO1997048380A1 (en) | 1996-06-20 | 1997-06-18 | ADMINISTRATION REGIMEN OF H+, K+-ATPase INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO985964D0 NO985964D0 (no) | 1998-12-18 |
| NO985964L NO985964L (no) | 1999-02-22 |
| NO323295B1 true NO323295B1 (no) | 2007-03-05 |
Family
ID=20403092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19985964A NO323295B1 (no) | 1996-06-20 | 1998-12-18 | Anvendelse av H+,K+-ATPase-inhibitorer for fremstilling av oralt administrerbare medikamenter for inhibering av magesyresekresjon |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US20010008900A1 (xx) |
| EP (1) | EP0921787B1 (xx) |
| JP (1) | JP2000512993A (xx) |
| CN (1) | CN1178648C (xx) |
| AT (1) | ATE252885T1 (xx) |
| AU (1) | AU726859B2 (xx) |
| BR (1) | BR9709838A (xx) |
| CA (1) | CA2257405A1 (xx) |
| CZ (1) | CZ298213B6 (xx) |
| DE (1) | DE69725860T2 (xx) |
| DK (1) | DK0921787T3 (xx) |
| EE (1) | EE04606B1 (xx) |
| ES (1) | ES2208921T3 (xx) |
| HK (1) | HK1018590A1 (xx) |
| HU (1) | HUP9901794A3 (xx) |
| IL (2) | IL127542A0 (xx) |
| IS (1) | IS2216B (xx) |
| NO (1) | NO323295B1 (xx) |
| NZ (1) | NZ332990A (xx) |
| PL (1) | PL189716B1 (xx) |
| PT (1) | PT921787E (xx) |
| RS (1) | RS49590B (xx) |
| RU (1) | RU2203662C2 (xx) |
| SE (1) | SE9602442D0 (xx) |
| SK (1) | SK284204B6 (xx) |
| TR (1) | TR199802647T2 (xx) |
| UA (1) | UA64715C2 (xx) |
| WO (1) | WO1997048380A1 (xx) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
| SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
| AU3870599A (en) * | 1998-04-30 | 1999-11-16 | Sepracor, Inc. | R-rabeprazole compositions and methods |
| WO1999055158A1 (en) * | 1998-04-30 | 1999-11-04 | Sepracor Inc. | S-rabeprazole compositions and methods |
| US6093734A (en) * | 1998-08-10 | 2000-07-25 | Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin | Prodrugs of proton pump inhibitors |
| IL141083A0 (en) | 1998-08-10 | 2002-02-10 | Partnership Of Michael E Garst | Prodrugs of proton pump inhibitors |
| WO2000009092A1 (en) | 1998-08-12 | 2000-02-24 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles |
| US20050048077A1 (en) * | 2002-02-21 | 2005-03-03 | George Sachs | Compositions, test kits and methods for detecting helicobacter pylori |
| MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| WO2006009602A2 (en) | 2004-06-16 | 2006-01-26 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
| MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
| GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
| GB0720220D0 (en) | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
| GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
| GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US5330982A (en) * | 1986-12-17 | 1994-07-19 | Glaxo Group Limited | Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith |
| WO1994024867A1 (en) * | 1993-04-27 | 1994-11-10 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
| SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| DE69522921T2 (de) * | 1994-07-08 | 2002-04-11 | Astrazeneca Ab | Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i) |
| US6132768A (en) * | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
| US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
-
1996
- 1996-06-20 SE SE9602442A patent/SE9602442D0/xx unknown
-
1997
- 1997-06-18 SK SK1655-98A patent/SK284204B6/sk not_active IP Right Cessation
- 1997-06-18 EE EE9800435A patent/EE04606B1/xx not_active IP Right Cessation
- 1997-06-18 PL PL97330910A patent/PL189716B1/pl not_active IP Right Cessation
- 1997-06-18 CN CNB971955387A patent/CN1178648C/zh not_active Expired - Fee Related
- 1997-06-18 NZ NZ332990A patent/NZ332990A/xx unknown
- 1997-06-18 DK DK97930933T patent/DK0921787T3/da active
- 1997-06-18 CA CA002257405A patent/CA2257405A1/en not_active Abandoned
- 1997-06-18 EP EP97930933A patent/EP0921787B1/en not_active Expired - Lifetime
- 1997-06-18 HU HU9901794A patent/HUP9901794A3/hu unknown
- 1997-06-18 TR TR1998/02647T patent/TR199802647T2/xx unknown
- 1997-06-18 JP JP10502822A patent/JP2000512993A/ja active Pending
- 1997-06-18 IL IL12754297A patent/IL127542A0/xx active IP Right Grant
- 1997-06-18 AU AU34690/97A patent/AU726859B2/en not_active Ceased
- 1997-06-18 UA UA99010150A patent/UA64715C2/uk unknown
- 1997-06-18 WO PCT/SE1997/001098 patent/WO1997048380A1/en active IP Right Grant
- 1997-06-18 PT PT97930933T patent/PT921787E/pt unknown
- 1997-06-18 CZ CZ0420398A patent/CZ298213B6/cs not_active IP Right Cessation
- 1997-06-18 US US08/945,425 patent/US20010008900A1/en not_active Abandoned
- 1997-06-18 BR BR9709838A patent/BR9709838A/pt not_active Application Discontinuation
- 1997-06-18 RU RU99101081/14A patent/RU2203662C2/ru not_active IP Right Cessation
- 1997-06-18 ES ES97930933T patent/ES2208921T3/es not_active Expired - Lifetime
- 1997-06-18 DE DE69725860T patent/DE69725860T2/de not_active Expired - Fee Related
- 1997-06-18 AT AT97930933T patent/ATE252885T1/de not_active IP Right Cessation
-
1998
- 1998-12-09 RS YUP-566/98A patent/RS49590B/sr unknown
- 1998-12-13 IL IL127542A patent/IL127542A/en not_active IP Right Cessation
- 1998-12-15 IS IS4923A patent/IS2216B/is unknown
- 1998-12-18 NO NO19985964A patent/NO323295B1/no not_active IP Right Cessation
-
1999
- 1999-08-06 HK HK99103406A patent/HK1018590A1/xx not_active IP Right Cessation
-
2004
- 2004-06-18 US US10/871,506 patent/US20050113418A1/en not_active Abandoned
-
2006
- 2006-10-05 US US11/544,956 patent/US20070276007A1/en not_active Abandoned
-
2008
- 2008-09-30 US US12/242,006 patent/US20090036494A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323295B1 (no) | Anvendelse av H+,K+-ATPase-inhibitorer for fremstilling av oralt administrerbare medikamenter for inhibering av magesyresekresjon | |
| RU2252032C2 (ru) | Новое применение соединений в качестве антибактериальных средств | |
| Wolfe et al. | Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome | |
| RO115780B1 (ro) | Combinatie sinergica | |
| Sachs et al. | Gastric acid-dependent diseases: a twentieth-century revolution | |
| Graham et al. | Omeprazole versus placebo in duodenal ulcer healing: the United States experience | |
| KR100483092B1 (ko) | H+,k+-atp아제억제제의투여방법 | |
| EP1353624B1 (en) | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination | |
| JP5303093B2 (ja) | テナトプラゾール及びヒスタミンｈ２受容体拮抗剤を組み合わせた医薬組成物 | |
| UA77812C2 (en) | Anelated pyrrol substances as proton pump inhibitors for treating gastric ulcer | |
| Rauws et al. | Peptic ulcer disease | |
| CN101138563A (zh) | 治疗消化性溃疡药物组合物 | |
| AU725697B2 (en) | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia | |
| Falk | Omeprazole: a new drug for the treatment of acid-peptic diseases | |
| Range | Package Insert |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |